Update re AbC-19TM Rapid Test & Launch of COVID-19 antibody laboratory-based testing service
26 January 2021
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes today’s update from Abingdon Health plc (AIM: ABDX) (“Abingdon Health”) regarding the AbC-19TM Rapid Test, confirming their expectations for future supply arrangements with the Department of Health and Social Care, the ongoing efforts to obtain regulatory approvals in a total of 27 geographies, and the ongoing work to build data the set(s) around the use-case for the AbC-19TM Rapid Test alongside vaccines.
In addition, Omega will today announce the launch of its COVID-19 antibody lab-based testing service in Littleport, Cambridgeshire (see separate RNS Reach for details), using the Mologic ELISA1 antibody test. This service will be offered to commercial occupational health partners, clinics and health care professionals in the UK.
Colin King, CEO of Omega Diagnostics, said: “We welcome the update from Abingdon Health this morning and look forward to being able to update investors on the potential to open up significant commercial opportunities outside of the UK in due course.”
1ELISA (Enzyme Linked Immuno-Sorbent Assay)
|Omega Diagnostics Group PLC||Tel: 01259 763 030|
|Bill Rhodes, Interim Non-Executive Chairman |
Colin King, Chief Executive
|Kieron Harbinson, Group Finance Director|
|finnCap Ltd||Tel: 020 7220 0500|
|Geoff Nash/Edward Whiley (Corporate Finance)|
|Alice Lane (ECM)|
|Walbrook PR Limited||Tel: 020 7933 8780 or [email protected]|
|Paul McManus||Mob: 07980 541 893|
|Lianne Cawthorne||Mob: 07584 391 303|